Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Superiority Study Comparing the Safety and Efficacy of SNP-ACTH (1-39) Gel Compared to Rituximab and FDA Approved Biosimilars in Adults With Primary Membranous Nephropathy (PMN) in a Two-Phase Adaptive Trial Design

NCT05696613 is registered in ClinicalTrials.gov with Cerium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05696613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05696613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Superiority Study Comparing the Safety and Efficacy of SNP-ACTH (1-39) Gel Compared to Rituximab and FDA Approved Biosimilars in Adults With Primary Membranous Nephropathy (PMN) in a Two-Phase Adaptive Trial Design
Lead sponsor
Cerium Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
March 13, 2023
Completion date
December 31, 2027
Enrollment
148 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy